Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04028531 · ClinicalTrials.gov registry record
Understanding Chronic Lymphocytic Leukemia
A clinical trial of Chronic Lymphocytic Leukemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 2,750
- Enrollment target
- 1
- Study location
NCT04028531 is a study of Chronic Lymphocytic Leukemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 2,750 participants, above the 167-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (1547% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04028531, a study of Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 2,750 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
Conditions Studied
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,750 participants |
| Start Date | 1999-09-29 |
| Est. Completion | 2032-09-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04028531
The ClinicalTrials.gov registry entry for NCT04028531 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,750 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 167-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (1547% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT04028531 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04028531 about?
NCT04028531 is a clinical study titled "Understanding Chronic Lymphocytic Leukemia". The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
What is the current status of trial NCT04028531?
This trial is currently recruiting. The enrollment target is 2,750 participants. The study started on 1999-09-29. Estimated completion is 2032-09-29.
What conditions does trial NCT04028531 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
Who is sponsoring clinical trial NCT04028531?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04028531 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.